These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33595174)

  • 1. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data.
    Misgav M; Brutman-Barazani T; Budnik I; Avishai E; Schapiro J; Bashari D; Barg AA; Lubetsky A; Livnat T; Kenet G
    Haemophilia; 2021 Mar; 27(2):253-260. PubMed ID: 33595174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring.
    Barg AA; Budnik I; Avishai E; Brutman-Barazani T; Bashari D; Misgav M; Lubetsky A; Kuperman AA; Livnat T; Kenet G
    Haemophilia; 2021 May; 27(3):383-391. PubMed ID: 33892524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.
    McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L
    Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab treatment and monitoring in a paediatric cohort: real-world data.
    Barg AA; Livnat T; Budnik I; Avishai E; Brutman-Barazani T; Tamarin I; Bashari D; Misgav M; Kenet G
    Br J Haematol; 2020 Oct; 191(2):282-290. PubMed ID: 32656767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
    Ebbert PT; Xavier F; Seaman CD; Ragni MV
    Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry.
    van der Zwet K; de Kovel M; Motwani J; van Geet C; Nolan B; Glosli H; Escuriola Ettingshausen C; Königs C; Kenet G; Fischer K;
    Haemophilia; 2024 May; 30(3):685-692. PubMed ID: 38578720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emicizumab prophylaxis in infants: Single-centre experience.
    Levy-Mendelovich S; Greenberg-Kushnir N; Budnik I; Barg AA; Cohen O; Avishai E; Barazani-Brutman T; Livnat T; Kenet G
    Br J Haematol; 2024 Apr; 204(4):1375-1382. PubMed ID: 38266507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data on the use of emicizumab in patients with haemophilia A with and without inhibitors in Singapore.
    Lee MW; Cheong MA; Ng HJ; Tien SL; Lam JCM
    Ann Acad Med Singap; 2023 Nov; 52(11):580-589. PubMed ID: 38920147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
    Kenet G; Fujii T
    Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
    Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
    Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.
    Wang CP; Young G; Thornburg CD
    Expert Opin Drug Saf; 2021 Apr; 20(4):387-396. PubMed ID: 33612049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.
    Samelson-Jones BJ; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Raffini L
    Haemophilia; 2021 Jul; 27(4):591-598. PubMed ID: 34050689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors.
    Hassan E; Jonathan L; Jayashree M
    Haemophilia; 2021 Nov; 27(6):e698-e703. PubMed ID: 34628693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.